Lecanemab

Product

FDA-approved anti-amyloid antibody for Alzheimer's disease, marketed as Leqembi by Biogen and Eisai

3 stories

Experimental Drug Shows First-Ever Reduction in Tau Pathology and Cognitive Benefit in Early Alzheimer's Trial

Study Concludes Anti-Amyloid Alzheimer's Drugs Have No Clinically Meaningful Effect

Researchers Identify 'Death Switch' Mechanism in Alzheimer's Disease